Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Encorafenib + Binimetinib Access for Cancer
Recruiting3 awardsPhase 4
Saint Paul, Minnesota
This trial continues the use of cancer medications encorafenib and binimetinib for patients who benefited from them in previous studies. The drugs work by blocking proteins that help cancer cells grow. Encorafenib and binimetinib were first approved for use in combination to treat metastatic melanoma with specific BRAF mutations.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service